Back to News
Market Impact: 0.2
Zealand And Generate Biomedicines Team Up To Develop AI-Designed Therapies For Metabolic Diseases
Source: Nasdaq
Artificial IntelligenceHealthcare & Biotech
Zealand Pharma and Generate Biomedicines are combining their expertise to develop treatments for obesity and other metabolic diseases, with artificial intelligence playing an increasing role in drug development. The report provides no deal terms, development milestones, or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
Ticker Sentiment
GENB0.40
ZEAL0.40
More News
- Anthropic's third-quarter revenue is said to hit $16.8 billion ahead of IPO
- Why is Samsung Electronics stock plunging today?
- SK Hynix plunges 8% amid Asia tech rout as Fed rate hike fears, AI funding worries mount
- Dell stock plunges 11%, leading data center sell-off on concerns about 'enterprise AI timing'
- US Stocks Tumble as Chip Rout Deepens
- Here's the inflation breakdown for September 2026 — in one chart